UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt (Chairperson & CEO of United Therapeutics) exercised 9,500 stock options and sold 9,480 shares of UTHR common stock indirectly via a family trust on July 17, 2026 under a 10b5-1 plan.

On July 17, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt, through an indirect family trust, exercised 9,500 stock options for common stock at an exercise price of $135.42 per share and acquired the corresponding 9,500 shares, then sold 9,480 shares of common stock on the same day in a series of open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The sales occurred in multiple tranches at prices ranging from approximately $528.91 to $542.43 per share, generating total sale proceeds of roughly $5.1 million, while the option exercise cost was about $1.3 million. Following these transactions, the reporting person continued to hold substantial indirect ownership in United Therapeutics common stock through various family trusts and spouse holdings, with the principal trust position shown as 324,443 shares and aggregate indirect trust and spouse holdings exceeding 630,000 shares, implying a post-transaction indirect equity stake worth on the order of $340 million based on the transaction price levels.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000101

Alert Tier

7